Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
Bristol Myers Squibb (BMY) shared preliminary Phase 3 data for KarXT in treating psychosis linked to Alzheimer's. ADEPT-1 showed improvements in hallucination and delusion scores over 12 weeks. ADEPT-3 reported long-term safety and tolerability data over 52 weeks. Both studies observed symptom score improvements and a favorable safety profile.
How this was made
The 30-second read
Why it matters
The disclosure is the first clinical data from the Phase 3 ADEPT program, showing clinician-observed improvements in hallucinations and delusions and reporting tolerability without new safety signals, but it does not yet reveal efficacy from the blinded treatment periods.
Market read
Traders may reassess KarXT’s Phase 3 probability of success based on preliminary symptom improvements and tolerability, while awaiting blinded efficacy and relapse outcomes.
What to watch
TEAE and discontinuation rates are not negligible, and the study’s primary endpoint is time to relapse during the blinded withdrawal period, which is not yet reported.
Background
BMY is evaluating KarXT (xanomeline plus trospium) in the Phase 3 ADEPT program for psychosis associated with Alzheimer’s disease, with multiple studies including ADEPT-1 and a long-term ADEPT-3 rollover extension.
Ticker impact
Bristol Myers Squibb disclosed first Phase 3 ADEPT program clinical data for KarXT, including 12-week and 52-week open-label symptom improvements and no new safety signals.
Likely modest upward bias as traders price improved probability of efficacy and tolerability, tempered by uncertainty until blinded data.
The article provides new, company-specific clinical readouts with quantified score reductions and safety summaries, but it is explicitly preliminary and based on descriptive analyses from open-label periods.
Market effects
Adds incremental momentum to Alzheimer’s psychosis drug development narratives and may increase attention on CNS/neurology trial readouts.
Limited direct regional spillover; primarily affects US-listed biotech sentiment.
Moderate global relevance as CTAD is an international conference and the ADEPT program is global Phase 3.
Counterpoint
Open-label, descriptive analyses can overstate benefit; without double-blind period results, the market may fade the initial enthusiasm.
Key entities
- companyBristol Myers Squibb
Sponsor of the ADEPT Phase 3 program evaluating KarXT for psychosis associated with Alzheimer’s disease.
- drugKarXT (xanomeline and trospium chloride)
Investigational oral therapy being studied for Alzheimer’s-associated psychosis; already FDA-approved as Cobenfy for schizophrenia.
- clinical_trialADEPT-1
Phase 3 randomized, double-blind placebo-controlled relapse prevention study with a 12-week open-label lead-in period.
- clinical_trialADEPT-3
Phase 3 52-week open-label extension rollover study assessing long-term safety and tolerability.
- conferenceCTAD Conference
Clinical Trials on Alzheimer’s Disease conference where the preliminary data were presented.




